ENDRA Life Sciences (NDRA) Stock Price, News & Analysis

Company Overview

ENDRA Life Sciences Inc. (NASDAQ: NDRA) is a medical technology company focused on developing and commercializing advanced imaging solutions for clinical and preclinical applications. The company’s proprietary Thermo Acoustic Enhanced Ultrasound (TAEUS) platform uses patented nanoemulsion-based contrast agents to generate high-resolution thermal maps of tissue. By combining ultrasound with thermoacoustic technology, ENDRA’s systems aim to provide clinicians with quantitative insights into tissue composition, addressing unmet needs in monitoring liver health, cancer therapy response and other disease states.

Founded in 2009 and headquartered in Ann Arbor, Michigan, ENDRA has evolved from a research-driven start-up into a publicly traded entity following a Nasdaq listing in late 2014. Since its inception, the firm has collaborated with leading academic institutions and secured regulatory designations to support its clinical development programs. The company’s Strata™ platform is designed for noninvasive, point-of-care imaging of liver steatosis, while additional preclinical systems target drug development workflows by enabling real-time assessment of tissue changes in oncology and cardiovascular research models.

ENDRA serves a range of geographies, with its principal markets in the United States and ongoing initiatives to expand into Europe and Asia through partnerships and clinical studies. The company’s leadership team combines experience in medical device innovation, regulatory affairs and commercialization. Under the direction of CEO Samer Nassif and Chief Medical Officer Sainil Harle, ENDRA continues to advance its TAEUS technology through pivotal trials, seeking to address growing healthcare challenges related to liver disease prevalence and the need for more effective imaging modalities.

Key Stats

• Today's Range: $7.61 to $8.10
• 50-Day Range: $3.09 to $8.84
• 52-Week Range: $2.90 to $170.63
• Volume: 36,803 shs
• Average Volume: 533,229 shs
• Market Capitalization: $5.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $50.00
• Consensus Rating: Buy

ENDRA Life Sciences Stock Analysis - MarketRank™

ENDRA Life Sciences scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

ENDRA Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

ENDRA Life Sciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ENDRA Life Sciences are expected to grow in the coming year, from ($47.46) to ($15.38) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ENDRA Life Sciences is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ENDRA Life Sciences is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ENDRA Life Sciences has a P/B Ratio of 1.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.10% of the float of ENDRA Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

ENDRA Life Sciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ENDRA Life Sciences has recently decreased by 6.51%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ENDRA Life Sciences does not currently pay a dividend.

Dividend Growth

ENDRA Life Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.10% of the float of ENDRA Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

ENDRA Life Sciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ENDRA Life Sciences has recently decreased by 6.51%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

ENDRA Life Sciences has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for ENDRA Life Sciences this week, compared to 0 articles on an average week.

Search Interest

6 people have searched for NDRA on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ENDRA Life Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.04% of the stock of ENDRA Life Sciences is held by insiders.

Percentage Held by Institutions

Only 1.19% of the stock of ENDRA Life Sciences is held by institutions.

NDRA Stock Analysis - Frequently Asked Questions

How have NDRA shares performed this year?

ENDRA Life Sciences' stock was trading at $6.26 at the beginning of the year. Since then, NDRA stock has increased by 23.1% and is now trading at $7.7060.

How were ENDRA Life Sciences' earnings last quarter?

ENDRA Life Sciences Inc. (NASDAQ:NDRA) posted its quarterly earnings results on Monday, March, 31st. The company reported ($9.40) earnings per share for the quarter, missing the consensus estimate of ($4.10) by $5.30.

When did ENDRA Life Sciences' stock split?

ENDRA Life Sciences shares reverse split before market open on Tuesday, August 20th 2024.The 1-50 reverse split was announced on Friday, August 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 19th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

When did ENDRA Life Sciences IPO?

ENDRA Life Sciences (NDRA) raised $10 million in an initial public offering (IPO) on Friday, February 3rd 2017. The company issued 2,000,000 shares at a price of $5.00-$5.50 per share. Dougherty & Company and Dawson James Securities acted as the underwriters for the IPO.

How do I buy shares of ENDRA Life Sciences?

Shares of NDRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ENDRA Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ENDRA Life Sciences investors own include Bionano Genomics (BNGO), Cocrystal Pharma (COCP), AMC Entertainment (AMC), Plug Power (PLUG), Mustang Bio (MBIO), SNDL (SNDL) and BIOLASE (BIOL).

Company Calendar

• Last Earnings: 3/31/2025
• Today: 7/15/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NDRA
• CIK: 1681682
• Web: www.endrainc.com
• Phone: (734) 335-0468
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for ENDRA Life Sciences: $50.00
• High Price Target: $50.00
• Low Price Target: $50.00
• Potential Upside/Downside: +519.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($172.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.51 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -140.96%
• Return on Assets: -106.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.85
• Quick Ratio: 3.85

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.77 per share
• Price / Book: 1.69

Miscellaneous

• Outstanding Shares: 740,000
• Free Float: 738,000
• Market Cap: $5.97 million
• Optionable: Not Optionable
• Beta: -0.18